• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
  • JOBS
No Result
View All Result
The London Economic
No Result
View All Result
Home Lifestyle Health

New breakthrough for aggressive blood cancer

Developed by British scientists, it identifies those with the most lethal types of lymphoma who are less likely to respond to standard drugs

Ben Gelblum by Ben Gelblum
2018-12-03 21:05
in Health, Science
FacebookTwitterLinkedinEmailWhatsapp

A new tool for treating an aggressive form of blood cancer has been developed by British scientists.

It identifies those with the most lethal types of lymphoma who are less likely to respond to standard drugs.

Lymphomas arise when immune cells called lymphocytes become cancerous. There are two types: B-cells and T-cells.

They look the same under the microscope but the revolutionary technique found one in ten patients are half as likely to be cured with existing treatments.

Known as gene expression profiling it finds twice as many as previous methods.

Senior author Professor David Westhead, a biological scientist at Leeds University, said: “We have discovered which patients will be left at greater risk by only receiving standard treatment, and at nearly 10% of patients sufferers, it is a significant group.”

Diffuse large B-cell lymphoma affects almost 5,000 people in the UK every year – and is the most common form of the disease.

RelatedPosts

Plastic food packaging can contain hundreds of chemicals and serious damage to humans is revealed

Brexit: Britain can’t access vast EU science funding due to ongoing tensions

New prostate treatment is being rolled out across the UK

Women are almost as likely to use social media for health advice as NHS, study finds

An analysis of the DNA of tumour cells from almost 1,000 patients discovered a group for whom they were much less effective.

It used complex computer models to examine 20,000 genes which make up the complete structure of human cells.

People with the ‘high grade’ tumours have a three-year survival rate after standard treatment of only about 37% – compared to 72% for all other cases.

Senior author Professor Ming-Qing Du, a pathologist at Cambridge University, said: “By identifying the molecular high grade group we have found the number of people who have a high chance of their lymphoma responding poorly to existing treatment is double what we expected.

“This should be a spur for pathologists to urgently re-assess the way we make the diagnosis so appropriate therapy can be tailored to the individual.”

The study published, in the Journal of Clinical Oncology, is part of a programme funded by the blood cancer charity Bloodwise.

This is a collaboration between a number of UK universities that is identifying more effective lymphoma drugs for people who do not respond to current treatments.

Senior author Prof Peter Johnson, an oncologist at Southampton University, said: “At the moment the standard treatment for this type of lymphoma is to use the R-CHOP combination of drugs.”

This includes antibodies andf chemotherapy but for patients with high grade lymphoma this may not be the best approach.

Prof Johnson said: “We need to make sure we identify them early on so we can consider different forms of treatment.

“At the moment we can use more intensive chemotherapy but by understanding the biology better we hope we can test more selective treatments with targeted agents.”

Dr Alasdair Rankin, director of Bloodwise, added: “This important research is tackling the challenge of accurately identifying lymphoma patients who will and won’t respond well to standard drugs.

“The next step will be to develop this approach for use in the NHS, so that more lives can be saved.”

By Ben Gelblum and Mark Waghorn

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Prolonged drought caused collapse of Maya civilisation about one thousand years ago

Slowest police chase ever as officers pursue digger escaping building site at 3mph

Football Friday – Weekend Preview

Tory peer warns failure to address islamophobia risks damaging party in next election after report that BAME voters feel unwelcome in Conservative Party

Water Fooler: See if you can hydrate in the Highlands

Watch: Corbyn says MI5 and MI6 undermined him as he calls Guardian ‘tool of the British establishment’

Watch: talkRADIO host suggests chickens wear masks to combat bird flu

Restaurant Review – Galley

Last day before train operator Northern hits buffers

VIDEO – Mock terror attack at UK shopping centre

JOBS

FIND MORE JOBS

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • JOBS
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.